Chapter 26. Evolving DNA Repair Targets for Cancer Therapy

Inhibition of Human APE1 and MTH1 DNA Repair Proteins by Dextran-Coated γ-Fe 2 O 3 Ultrasmall Superparamagnetic Iron Oxide Nanoparticles

“…MTH1 has been shown to be required by cancer cells for survival by preventing the incorporation of modified dNTPs that would lead to cell death; therefore, it is a promising target in cancer therapy [ 9 , 10 ]. There are numerous ongoing clinical trials specifically focused on the application of small-molecule inhibitors of DNA repair proteins as anticancer agents ( https://clinicaltrials.gov ) [ 3 , 11–13 ]. Some of these compounds, such as PARP1 inhibitors olaparib, rucaparib and niraparib, have already been approved by the US FDA.…”

Inhibition by Tetrahydroquinoline Sulfonamide Derivatives of the Activity of Human 8-Oxoguanine DNA Glycosylase (OGG1) for Several Products of Oxidatively induced DNA Base Lesions

“…Cancer cells increase their DNA repair capacity by overexpressing DNA repair proteins, leading to drug or radiation resistance in cancer therapy. Several inhibitors of DNA repair proteins are approved or are under development as potential anticancer drugs (reviewed in refs − ).…”